KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to $84.2 billion.

  • Abbott Laboratories' Liabilities and Shareholders Equity rose 1321.35% to $84.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $331.0 billion, marking a year-over-year increase of 1296.28%. This contributed to the annual value of $81.4 billion for FY2024, which is 1120.0% up from last year.
  • As of Q3 2025, Abbott Laboratories' Liabilities and Shareholders Equity stood at $84.2 billion, which was up 1321.35% from $84.0 billion recorded in Q2 2025.
  • Abbott Laboratories' 5-year Liabilities and Shareholders Equity high stood at $84.2 billion for Q3 2025, and its period low was $21.2 billion during Q4 2021.
  • Over the past 5 years, Abbott Laboratories' median Liabilities and Shareholders Equity value was $73.4 billion (recorded in 2023), while the average stood at $69.9 billion.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 22777.01% in 2023, then tumbled by 179.82% in 2024.
  • Over the past 5 years, Abbott Laboratories' Liabilities and Shareholders Equity (Quarter) stood at $21.2 billion in 2021, then rose by 5.49% to $22.3 billion in 2022, then skyrocketed by 227.77% to $73.2 billion in 2023, then grew by 11.2% to $81.4 billion in 2024, then rose by 3.4% to $84.2 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $84.2 billion for Q3 2025, versus $84.0 billion for Q2 2025 and $81.4 billion for Q1 2025.